Who are Inhaled Epoprostenol and phenylephrine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inhaled-epoprostenol-and-phenylephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Inhaled Epoprostenol and phenylephrine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhaled Epoprostenol and phenylephrine (Inhaled Epoprostenol and phenylephrine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analog with alpha-1 adrenergic agonist. Area: Cardiovascular.

marketed Prostacyclin analog with alpha-1 adrenergic agonist Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Inhaled Epoprostenol and phenylephrine (Inhaled Epoprostenol and phenylephrine) — University Health Network, Toronto. Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inhaled Epoprostenol and phenylephrine TARGET	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analog with alpha-1 adrenergic agonist class)

University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inhaled Epoprostenol and phenylephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/inhaled-epoprostenol-and-phenylephrine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab